Login to Your Account

European Crohn's, Colitis group supports switch from infliximab to Celltrion's biosimilar

By Haky Moon
Staff Writer

Wednesday, December 14, 2016

HONG KONG – Celltrion Inc. has much to look forward to in the European market, where perception on biosimilars is shifting for the better. The Congress of the European Crohn's and Colitis Organisation announced its support for switching from reference Remicade (infliximab, Janssen Biotech Inc.), the blockbuster anti-inflammatory drug, to biosimilar infliximab.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription